Q1 Earnings Estimate for TLSI Issued By Northland Securities

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Research analysts at Northland Securities issued their Q1 2026 earnings per share estimates for TriSalus Life Sciences in a research note issued on Friday, March 6th. Northland Securities analyst C. Byrnes anticipates that the company will post earnings per share of ($0.12) for the quarter. The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Northland Securities also issued estimates for TriSalus Life Sciences’ FY2027 earnings at ($0.20) EPS.

TLSI has been the subject of several other research reports. Wall Street Zen upgraded shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday. Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Friday, March 6th. Zacks Research upgraded TriSalus Life Sciences from a “strong sell” rating to a “hold” rating in a research note on Tuesday, December 16th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences has an average rating of “Hold” and an average price target of $7.00.

TriSalus Life Sciences Price Performance

Shares of NASDAQ TLSI opened at $4.26 on Monday. The company has a 50 day simple moving average of $5.27 and a 200-day simple moving average of $5.36. The company has a market capitalization of $213.26 million, a P/E ratio of -2.33 and a beta of 0.42. TriSalus Life Sciences has a 1 year low of $3.42 and a 1 year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. The firm had revenue of $13.21 million for the quarter, compared to analysts’ expectations of $13.20 million.

Institutional Investors Weigh In On TriSalus Life Sciences

Large investors have recently bought and sold shares of the stock. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of TriSalus Life Sciences in the second quarter valued at $29,000. JPMorgan Chase & Co. increased its position in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $47,000. Invesco Ltd. purchased a new position in TriSalus Life Sciences in the fourth quarter valued at about $72,000. Finally, Abel Hall LLC purchased a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at about $73,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.